60% Increase: Why DexCom Is the Best Healthcare Investment Available
December 12, 2023
☀️Trending News
DEXCOM ($NASDAQ:DXCM): I firmly believe that DexCom is one of the best healthcare investments available today. With its stock value increasing by 60%, DexCom has proven itself to be a strong and reliable source of financial gains. The company, which specializes in medical device development, has made major strides in revolutionizing diabetes care by providing continuous glucose monitoring (CGM) products and services. By leveraging its patented technology, DexCom has created a platform that allows diabetes patients to have access to real-time glucose data and insights, as well as personalized alerts to help them manage their condition more effectively. The company also offers a variety of other services and products that are designed to help individuals with diabetes monitor and manage their condition more easily.
Additionally, DexCom offers a range of mobile services that provide insights into how lifestyle choices affect glucose levels, helping patients make smarter decisions for better outcomes. Overall, I believe that DexCom’s impressive 60% stock value increase is indicative of the company’s potential for success and growth in the healthcare industry. With its cutting-edge technology, comprehensive product suite, and dedication to innovation, DexCom is an excellent investment for anyone looking for a secure and reliable source of income.
Analysis
As GoodWhale, we have recently completed an analysis of DEXCOM’s fundamentals. Based on our Star Chart, DEXCOM is classified as a ‘gorilla’, meaning that it has achieved stable and high revenue or earnings growth due to its strong competitive advantage. Therefore, we believe that the company may be of interest to many types of investors, including those who are looking for long-term growth and stability as well as those who are interested in capital appreciation. In terms of financial health, DEXCOM has a high score of 10/10 on our health index. This means that the company is capable to safely ride out any crisis without the risk of bankruptcy, due to its strong cashflows and debt. We have also found that DEXCOM is strong in terms of asset, growth, and profitability, although it is weak in dividend. Therefore, it may be more suitable for investors who are looking for capital appreciation rather than income. DexCom_Is_the_Best_Healthcare_Investment_Available”>More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Dexcom. DexCom_Is_the_Best_Healthcare_Investment_Available”>More…
| Total Revenues | Net Income | Net Margin |
| 3.4k | 377 | 11.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dexcom. DexCom_Is_the_Best_Healthcare_Investment_Available”>More…
| Operations | Investing | Financing |
| 747.4 | -1.12k | 312.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dexcom. DexCom_Is_the_Best_Healthcare_Investment_Available”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.6k | 4.33k | 5.87 |
Key Ratios Snapshot
Some of the financial key ratios for Dexcom are shown below. DexCom_Is_the_Best_Healthcare_Investment_Available”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 23.2% | 19.5% | 18.1% |
| FCF Margin | ROE | ROA |
| 14.7% | 17.7% | 5.9% |
Peers
The company was founded in 1999 and is headquartered in San Diego, California. DexCom has a market cap of $15.8 billion as of May 2020. The company’s competitors include Abbott Laboratories, Insulet Corp, and Medtronic PLC.
– Abbott Laboratories ($NYSE:ABT)
Abbott Laboratories is a publicly traded healthcare company with a market capitalization of $173.42 billion as of 2022. The company’s return on equity is 16.7%. Abbott Laboratories is a diversified healthcare company that develops and manufactures a wide range of products and services for the treatment of various medical conditions. The company’s product portfolio includes pharmaceuticals, diagnostics, medical devices, and nutritional products. Abbott Laboratories has a strong presence in both developed and emerging markets.
– Insulet Corp ($NASDAQ:PODD)
Insulet Corporation is a medical device company that manufactures and sells insulin delivery systems for people with diabetes. The company was founded in 2000 and is headquartered in Massachusetts, United States. Insulet Corporation has a market capitalization of 20.48 billion as of 2022 and a return on equity of 8.72%. The company’s products include the OmniPod insulin pump, the PodderPrep insulin pump starter kit, and the mylife Pods insulin pump cartridges.
– Medtronic PLC ($NYSE:MDT)
Medtronic PLC is a medical device company that focuses on providing treatments for cardiovascular diseases, diabetes, and neurological disorders, among others. As of 2022, the company has a market cap of 105.39B and a return on equity of 7.49%. Medtronic PLC is headquartered in Dublin, Ireland.
Summary
DEXCOM is a leading medical device technology company that specializes in developing and producing continuous glucose monitoring systems for people with diabetes. The company’s stock has seen significant growth over the last year, increasing by around 60%. This is attributed to its innovative products, strong financial performance, and expanding market opportunity.
As demand for diabetes care solutions continues to rise, and with its strong competitive advantage in the space, DEXCOM is well placed to capitalize on this growing market. DEXCOM’s strong financial performance, market position, and product portfolio make it an attractive stock for investors wanting to capitalize on its growth potential.
Related Posts
Recent Posts
